Primary amyloidosis epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
=== | ===Incidence=== | ||
*The [[incidence]] of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide.<ref name="pmid116772762">{{cite journal |vauthors=Khan MF, Falk RH |title=Amyloidosis |journal=Postgrad Med J |volume=77 |issue=913 |pages=686–93 |date=November 2001 |pmid=11677276 |pmc=1742163 |doi= |url=}}</ref> | |||
*The [[incidence]] of AL amyloidosis in USA ranged from 1 per 100,000 to 1.4 per 100,000 from 2007 to 2015.<ref name="pmid29748430">{{cite journal |vauthors=Quock TP, Yan T, Chang E, Guthrie S, Broder MS |title=Epidemiology of AL amyloidosis: a real-world study using US claims data |journal=Blood Adv |volume=2 |issue=10 |pages=1046–1053 |date=May 2018 |pmid=29748430 |pmc=5965052 |doi=10.1182/bloodadvances.2018016402 |url=}}</ref> | |||
*Transthyretin-related hereditary amyloidosis is endemic in Portuguese locations Póvoa de Varzim and Vila do Conde (Caxinas), with more than 1000 affected people, coming from about 500 families, where 70% of the people develop the illness. In northern Sweden, more specifically Piteå, Skellefteå and Umeå, 1.5% of the population has the mutated gene. There are many other populations in the world who exhibit the illness after having developed it independently. | |||
=== | ===Prevalence=== | ||
*The [[prevalence]] of AL in USA amyloidosis increased significantly between 2007 and 2015, from 1.6 per 100,000 in 2007 to 4.0 per 100,000 in 2015.<ref name="pmid297484302">{{cite journal |vauthors=Quock TP, Yan T, Chang E, Guthrie S, Broder MS |title=Epidemiology of AL amyloidosis: a real-world study using US claims data |journal=Blood Adv |volume=2 |issue=10 |pages=1046–1053 |date=May 2018 |pmid=29748430 |pmc=5965052 |doi=10.1182/bloodadvances.2018016402 |url=}}</ref> | |||
=== | ===Mortality rate=== | ||
*The [[mortality rate]] of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.<ref name="pmid16409147">{{cite journal |vauthors=Pepys MB |title=Amyloidosis |journal=Annu. Rev. Med. |volume=57 |issue= |pages=223–41 |date=2006 |pmid=16409147 |doi=10.1146/annurev.med.57.121304.131243 |url=}}</ref> | |||
=== Race === | ===Age=== | ||
*In amyloidosis, the [[mean]] age of presentation is 55-60 years.<ref name="pmid214940832">{{cite journal |vauthors=Shin YM |title=Hepatic amyloidosis |journal=Korean J Hepatol |volume=17 |issue=1 |pages=80–3 |date=March 2011 |pmid=21494083 |pmc=3304630 |doi=10.3350/kjhep.2011.17.1.80 |url=}}</ref> | |||
===Race=== | |||
*Hereditary amyloidosis subtypes include a substitution of an [[amino acid]] that is detected in approximately 4% of the black population.<ref name="pmid11677276">{{cite journal |vauthors=Khan MF, Falk RH |title=Amyloidosis |journal=Postgrad Med J |volume=77 |issue=913 |pages=686–93 |date=November 2001 |pmid=11677276 |pmc=1742163 |doi= |url=}}</ref> | |||
===Gender=== | |||
*Men are more commonly affected by amyloidosis than women.<ref name="pmid21494083">{{cite journal |vauthors=Shin YM |title=Hepatic amyloidosis |journal=Korean J Hepatol |volume=17 |issue=1 |pages=80–3 |date=March 2011 |pmid=21494083 |pmc=3304630 |doi=10.3350/kjhep.2011.17.1.80 |url=}}</ref> | |||
Latest revision as of 17:35, 30 October 2019
Primary amyloidosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Primary amyloidosis epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Primary amyloidosis epidemiology and demographics |
Primary amyloidosis epidemiology and demographics in the news |
Risk calculators and risk factors for Primary amyloidosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]
Overview
There are approximately 4000 new cases of AL amyloidosis annually in the United States, though actual incidence may be somewhat higher as a result of under-diagnosis. While the incidence is thought to be equal in males and females, about 60% of patients referred to amyloid centers are male. AL amyloidosis has been reported in individuals as young as 20 years of age but is typically diagnosed at about age 50-65.
Epidemiology and Demographics
Incidence
- The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide.[1]
- The incidence of AL amyloidosis in USA ranged from 1 per 100,000 to 1.4 per 100,000 from 2007 to 2015.[2]
- Transthyretin-related hereditary amyloidosis is endemic in Portuguese locations Póvoa de Varzim and Vila do Conde (Caxinas), with more than 1000 affected people, coming from about 500 families, where 70% of the people develop the illness. In northern Sweden, more specifically Piteå, Skellefteå and Umeå, 1.5% of the population has the mutated gene. There are many other populations in the world who exhibit the illness after having developed it independently.
Prevalence
- The prevalence of AL in USA amyloidosis increased significantly between 2007 and 2015, from 1.6 per 100,000 in 2007 to 4.0 per 100,000 in 2015.[3]
Mortality rate
- The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.[4]
Age
Race
- Hereditary amyloidosis subtypes include a substitution of an amino acid that is detected in approximately 4% of the black population.[6]
Gender
- Men are more commonly affected by amyloidosis than women.[7]
References
- ↑ Khan MF, Falk RH (November 2001). "Amyloidosis". Postgrad Med J. 77 (913): 686–93. PMC 1742163. PMID 11677276.
- ↑ Quock TP, Yan T, Chang E, Guthrie S, Broder MS (May 2018). "Epidemiology of AL amyloidosis: a real-world study using US claims data". Blood Adv. 2 (10): 1046–1053. doi:10.1182/bloodadvances.2018016402. PMC 5965052. PMID 29748430.
- ↑ Quock TP, Yan T, Chang E, Guthrie S, Broder MS (May 2018). "Epidemiology of AL amyloidosis: a real-world study using US claims data". Blood Adv. 2 (10): 1046–1053. doi:10.1182/bloodadvances.2018016402. PMC 5965052. PMID 29748430.
- ↑ Pepys MB (2006). "Amyloidosis". Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.
- ↑ Shin YM (March 2011). "Hepatic amyloidosis". Korean J Hepatol. 17 (1): 80–3. doi:10.3350/kjhep.2011.17.1.80. PMC 3304630. PMID 21494083.
- ↑ Khan MF, Falk RH (November 2001). "Amyloidosis". Postgrad Med J. 77 (913): 686–93. PMC 1742163. PMID 11677276.
- ↑ Shin YM (March 2011). "Hepatic amyloidosis". Korean J Hepatol. 17 (1): 80–3. doi:10.3350/kjhep.2011.17.1.80. PMC 3304630. PMID 21494083.